A clinical study of gene expression models for predicting chemotherapeutic response in patients with esophageal squamous cell carcinoma
Phase 2
- Conditions
- Patients who are suitable for a combination chemotherapy with cisplatin and 5-FU as a first-line treatment in esophageal squamous cell carcinoma.
- Registration Number
- JPRN-UMIN000007750
- Lead Sponsor
- Koshin Chemical Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)Not meeting the standards of eligibility 2)Pregnant female 3)Treated with combined radiotherapy or other anticancer drugs 4)Any other inappropriate state for participating to this study estimated by doctor in charge
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tumor response
- Secondary Outcome Measures
Name Time Method